LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

Inicio・Lista de Acciones・Erasca Inc

Erasca Inc

Cerrado

11.11 7.97

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

10.37

Máximo

11.43

Métricas clave
By Trading Economics
Ingresos	-154M -183M
BPA	-0.6
Empleados	103
EBITDA	-5.3M -37M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+96.41% upside

Dividendos
By Dow Jones
Próximas Ganancias	10 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-53M 3.2B
Apertura anterior	3.14
Cierre anterior	11.11

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

1.39 / 1.44 Soporte y Resistencia

Erasca Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

19 may 2026, 20:36 UTC

Adquisiciones, fusiones, absorciones

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

19 may 2026, 23:47 UTC

Charlas de Mercado

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

19 may 2026, 23:34 UTC

Charlas de Mercado

Gold Edges Higher on Possible Technical Recovery -- Market Talk

19 may 2026, 23:28 UTC

Charlas de Mercado

Ganancias

Global Forex and Fixed Income Roundup: Market Talk

19 may 2026, 23:28 UTC

Charlas de Mercado

Ganancias

F&P Healthcare's Outlook Key for Investors -- Market Talk

19 may 2026, 23:10 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

19 may 2026, 23:10 UTC

Charlas de Mercado

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

19 may 2026, 22:02 UTC

Ganancias

ZTO Express (Cayman): Di Xu to Resign From Board

19 may 2026, 22:01 UTC

Ganancias

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

19 may 2026, 22:01 UTC

Ganancias

ZTO Express (Cayman) 1Q EPS 39c >ZTO

19 may 2026, 22:00 UTC

Ganancias

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

19 may 2026, 21:37 UTC

Ganancias

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

19 may 2026, 21:31 UTC

Adquisiciones, fusiones, absorciones

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

19 may 2026, 21:01 UTC

Ganancias

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

19 may 2026, 20:58 UTC

Ganancias

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

19 may 2026, 20:46 UTC

Acciones populares

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

19 may 2026, 20:43 UTC

Charlas de Mercado

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

19 may 2026, 20:34 UTC

Ganancias

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

19 may 2026, 20:32 UTC

Ganancias

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

19 may 2026, 20:32 UTC

Ganancias

James Hardie Industries 4Q EPS 5c >JHX

19 may 2026, 20:32 UTC

Ganancias

James Hardie Industries 4Q Sales $1.4B >JHX

19 may 2026, 20:21 UTC

Adquisiciones, fusiones, absorciones

Analog Devices to Buy Empower Semiconductor for $1.5B

19 may 2026, 20:18 UTC

Charlas de Mercado

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

19 may 2026, 20:13 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

19 may 2026, 20:13 UTC

Charlas de Mercado

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

19 may 2026, 20:03 UTC

Adquisiciones, fusiones, absorciones

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

19 may 2026, 20:03 UTC

Adquisiciones, fusiones, absorciones

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

19 may 2026, 20:02 UTC

Adquisiciones, fusiones, absorciones

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

19 may 2026, 20:02 UTC

Adquisiciones, fusiones, absorciones

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

19 may 2026, 19:23 UTC

Charlas de Mercado

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Comparación entre iguales

Cambio de precio

Erasca Inc previsión

Precio Objetivo

By TipRanks

96.41% repunte

Estimación a 12 Meses

Media 20.27 USD 96.41%

Máximo 30 USD

Mínimo 9 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Erasca Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

11 ratings

Comprar

Mantener

Vender

De acuerdo con 11 analistas que ofrecen calificaciones bursátiles a para Erasca Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.39 / 1.44Soporte y Resistencia

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.